Navigation Links
Cell Therapeutics, Inc. Announces Institutional Investors Purchase Approximately $16.0 Million of Preferred Stock and Warrants
Date:4/27/2011

SEATTLE, April 28, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell, subject to customary closing conditions, approximately $16.0 million of shares of its Series 12 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to three institutional investors.  Each share of Series 12 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 2,857 shares of common stock at a conversion price of $0.35 per share of common stock, for a total of 45,634,286 shares of common stock.

In connection with the offering, the investors received warrants to purchase up to 18,253,714 shares of common stock.  The warrants have an exercise price of $0.40 per warrant share, for total potential additional proceeds to the Company of approximately $7.3 million upon exercise of the warrants for cash. The warrants are exercisable immediately and expire five years from the date of issuance.

The Company intends to use the net proceeds from the offering for general corporate purposes, which may include, among other things, paying interest on and/or retiring portions of its outstanding debt, funding research and development, preclinical and clinical trials, the preparation and filing of new drug applications and general working capital.  The Company may also use a portion of the net proceeds to fund possible investments in, or acquisitions of, complementary businesses, technologies or products.  The Company has recently engaged in limited discussions with third parties regarding such investments or acquisitions, but has no current agreements or commitments with respect to any investment or acquisition.

Shares of the Series 12 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock and have no voting ri
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. ... (NASDAQ: SRNE ;  Sorrento), an oncology ... pain, and Conkwest, Inc., a privately-held immuno-oncology company ... Killer (NK) cell-line based therapy, announced today that ... to jointly develop next generation CAR-TNK™ (pronounced as ...
(Date:12/19/2014)... Dec. 18, 2014  Sage Analytics ( www.sageanalytics.com ... equipment for the testing of marijuana potency and ... new Luminary™ Profiler, the industry,s first product suite ... a cost-effective, portable unit. Designed from ... of the cannabis industry, the Luminary™ Profiler utilizes ...
(Date:12/19/2014)... 18, 2014 Baptist Health Lexington is the first ... receive full Atrial Fibrillation with Electrophysiology Services (EPS) Accreditation status ... Atrial fibrillation is the most common cardiac arrhythmia and has ... can lead to stroke and possible death. More than 5 ... have atrial fibrillation and the numbers are rapidly increasing as ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3
... July 21 Caraco Pharmaceutical Laboratories, Ltd. (NYSE ... extended release tablets. This product was recently approved by ... Pharma,s Abbreviated New Drug Application (ANDA). These bupropion hydrochloride ... mg, are therapeutically equivalent to GlaxoSmithKline,s Wellbutrin SR® Extended ...
... Conn. , July 21 Cara Therapeutics, ... Series D financing of $15 million .  The ... participation from previous investors Alta Biopharma, Ascent Biomedical Ventures, ... International Corporation and MVM Life Science Partners. In conjunction ...
Cached Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Wellbutrin SR® Extended Release Tablets 2Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845 2Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845 3
(Date:12/19/2014)... -- A new study suggests a possible link between ... and night sweats -- and higher rates of hip ... during menopause, affecting about 60 percent of women. The ... since they then face a higher risk of weakened ... exhibit moderate or severe menopausal symptoms are more likely ...
(Date:12/19/2014)... Dotinga HealthDay Reporter ... including ibuprofen, might slightly reduce your risk of developing ... of ibuprofen (Advil, Motrin) and naproxen (Aleve) appear to ... 15 percent, the researchers concluded after reviewing nine prior ... sun exposure. These painkillers "have potential ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, ... leg for at least 20 seconds you may be at ... on one leg may indicate that small strokes or tiny ... serious strokes is high, the investigators reported online Dec. 18 ... while standing on one leg, as well as problems walking, ...
(Date:12/17/2014)... Mass. (PRWEB) December 17, 2014 ... of Osteopathic Medicine (ACOM), which welcomed its inaugural ... Desktop Infrastructure (VDI) to seamlessly support bring your ... – and teaching – experience. The solution, comprised ... NetScaler , Dell server and storage infrastructure ...
(Date:12/17/2014)... December 17, 2014 A group of 127 ... Longevity, today, in reaction to a recent statement by the ... brain training and derogated the efficacy of all brain exercises. ... with the parts of the center’s statement critical of brain ... center had also overstated its case, in a document it ...
Breaking Medicine News(10 mins):Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4
... (SAN FRANCISCO, December 6, 2008) Four studies highlighting ... sickle cell disease will be presented today at the ... in San Francisco, CA. , Results from a ... improve endothelial dysfunction, a malfunction in the inner lining ...
... The use of dexamethasone early in the treatment of children ... cancer, may help reduce the risk of relapse according to ... December 6, at 2:00 p.m., during the 50th Annual Meeting ... Additional research will be featured at the press conference that ...
... 2008) A study assessing the quality of care for ... settings will be presented at a press conference on Saturday, ... of the American Society of Hematology in San Francisco, CA. ... risk in children with sickle cell disease, as well as ...
... 6, 2008) Four studies that highlight significant advances ... forms of thrombocytopenia, a group of bleeding disorders characterized ... will be presented in a press conference on Saturday, ... Meeting of the American Society of Hematology in San ...
... a call from a biotech lab in Korea. He was told ... clone of a pet dog, his beloved family mutt, Missy. Now ... healthy puppy living the good life in Mill Valley, California. “Not ... coat feels the same, and she has some of the same ...
... for Leadership on Right to Health , ... Boston (Vocus) December 5, ... community members and experts join for a landmark town meeting titled ,HIV/AIDS ... event, which commemorates World AIDS Day and the 60th anniversary of the ...
Cached Medicine News:Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 2Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 3Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 4Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 5Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 6Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 7Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 2Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 3Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 4Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 5Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 6Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 7Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 8Health News:Studies examine quality of care for hospitalized sickle cell disease patients 2Health News:Studies examine quality of care for hospitalized sickle cell disease patients 3Health News:Studies examine quality of care for hospitalized sickle cell disease patients 4Health News:Studies examine quality of care for hospitalized sickle cell disease patients 5Health News:Studies examine quality of care for hospitalized sickle cell disease patients 6Health News:Studies examine quality of care for hospitalized sickle cell disease patients 7Health News:Studies examine quality of care for hospitalized sickle cell disease patients 8Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 2Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 3Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 4Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 5Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 6Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 7Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 8Health News:Cloned Canine Celebrates Her 1st Birthday 2Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 2Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 3Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 4Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 5Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 6
... is a long term, quality solution based ... both posterior stabilized and anatomically correct cruciate ... the flexibility needed to address patients' needs. ... identification keeps the user in mind and ...
... Iso-C3D C-Arm imaging system interface sets a ... C-arm imaging. Combining mobility and accurate ... cooperative technologies deliver the most complete perspective ... is the new standard in the OR. ...
... Radionics' new OmniSight image guided surgery ... maintaining simplicity in design and use. ... the neurosurgeon to localize critical anatomy ... new system gives surgeons an easy-to-use, ...
... are the next evolution in transforaminal lumbar ... sound instruments.. The T.L.I.F. SG Instruments feature ... disc preparation instruments designed to support the ... wide range of instrument options to meet ...
Medicine Products: